MinhajFS, OgaleYP, WhitehillF, et al.Monkeypox response team 2022. Monkeypox outbreak—nine states, May 2022. MMWR Morb Mortal Wkly Rep, 2022; 71(23):764–769. doi: 10.15585/mmwr.mm7123e1.
2.
FreySE, WaldA, EdupugantiS, et al.Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine, 2015; 33(39):5225–5234. doi: 10.1016/j.vaccine.2015.06.075.
3.
OvertonET, LawrenceSJ, WagnerE, et al.Immunogenicity and safety of three consecutive production lots of the non-replicating smallpox vaccine MVA: a randomised, double blind, placebo controlled phase III trial. PLoS One, 2018; 13(4):e0195897. doi: 10.1371/journal.pone.0195897.
4.
GreenbergRN, HurleyMY, DinhDV, et al.Multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18–40 year old subjects with diagnosed atopic dermatitis. PLoS One, 2015; 10(10):e0138348. doi: 10.1371/journal.pone.0138348. Erratum in: PLoS One 2015;10(11):e0142802. Hurley, Yadira [corrected to Hurley, Maria Yadira].
5.
GreenbergRN, HayCM, StapletonJT, et al.A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of modified vaccinia ankara smallpox vaccine (MVA-BN®) in 56-80-year-old subjects. PLoS One, 2016; 11(6):e0157335. doi: 10.1371/journal.pone.0157335.
